BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2026 8:53:13 AM | Browse: 3 | Download: 0
 |
Received |
|
2025-11-18 10:18 |
|
Peer-Review Started |
|
2025-11-18 10:19 |
|
First Decision by Editorial Office Director |
|
2025-12-18 09:34 |
|
Return for Revision |
|
2025-12-18 09:34 |
|
Revised |
|
2026-01-27 21:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-02 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-02 07:37 |
|
Articles in Press |
|
2026-03-02 07:37 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-29 08:11 |
|
Publish the Manuscript Online |
|
2026-05-20 08:53 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Laboratory Technology |
| Manuscript Type |
Basic Study |
| Article Title |
Overexpression of low-molecular-weight caldesmon is associated with aggressive phenotypes and epithelial-mesenchymal transition in breast cancer cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Alya AlNuaimi, Vidhya A Nair, Noura Al-Khayyal, Ashna Suliman, Lara J Bou Malhab, Rifat Hamoudi, Mohamad Hamad, Iman M Talaat and Wael M Abdel-Rahman |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wael M Abdel-Rahman, MD, PhD, Professor, Department of Medical Laboratory Sciences, College of Health Sciences, University of Sharjah, University City, Sharjah 27272, United Arab Emirates. whassan@sharjah.ac.ae |
| Key Words |
Low-molecular-weight caldesmon; Breast cancer; Triple-negative; Epithelial-mesenchymal transition; Invasion; Metastasis |
| Core Tip |
Low-molecular-weight caldesmon (l-CAD) plays a key role in triple-negative breast cancer (TNBC) progression by promoting epithelial-mesenchymal transition and enhancing cell motility and invasiveness. This study identifies CALD1 transcript variant 2 as the key isoform driving tumorigenesis in TNBC. Immunohistochemical analysis confirmed l-CAD expression in the cytoplasm and stroma of cancer cells and stromal cells, with significant associations with lymphovascular invasion and receptor status. High CALD1 levels in TNBC are associated with poor prognosis and reduced disease-free survival, highlighting l-CAD as a potential driver of metastasis and a promising prognostic biomarker. |
| Publish Date |
2026-05-20 08:53 |
| Citation |
AlNuaimi A, Nair VA, Al-Khayyal N, Suliman A, Bou Malhab LJ, Hamoudi R, Hamad M, Talaat IM, Abdel-Rahman WM. Overexpression of low-molecular-weight caldesmon is associated with aggressive phenotypes and epithelial-mesenchymal transition in breast cancer cells. World J Clin Oncol 2026; 17(5): 116662 |
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i5/116662.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v17.i5.116662 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
